In another study conducted on melanoma A375 cells, co-treatment with brusatol and ultraviolet A resulted in an inhibition of A375 cell proliferation and reduction of melanoma-derived tumor burden, and the anticancer effects were through triggering ROS-dependent apoptosis and blocking AKT-Nrf2 pathway 86. Here, AKT1 is linked to melanoma.